Skip to main content
Premium Trial:

Request an Annual Quote

Core Life Sciences to Distribute Biogazelle qPCR Software in California


Core Life Sciences said today that it has partnered with Belgium's Biogazelle to distribute its qbase+ qPCR software in California.

Based on geNorm and qBase technology developed by Ghent University's Jo Vandesompele and Jan Hellemans, qbase+ is qPCR data-analysis software designed for mRNA gene expression profiling and analysis, miRNA profiling and validation studies, and gene copy number analysis, among other applications.

The software provides "fast, flexible, and reliable qPCR analysis in an open format, with integrated proprietary algorithms and features that have been published in peer-reviewed journals," Core Life Sciences said in a statement.

In addition, qbase+ enables data normalization, quality control, and inter-run calibration, allowing users to "easily generate publication-ready results," the company said. The software is also compliant with the minimum information for publication of quantitative real-time PCR experiment (MIQE) guidelines.

Based in Laguna Niguel, Calif., Core Life Sciences is a distributor and service provider for microarray, PCR, electrophoresis, and microplate products for life science research.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.